The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring of heparin therapy. Recall
The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring of heparin therapy.
FDA recall Class II
Ongoing
FDA lists this Class II recall for The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring of heparin therapy.. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-1095-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Dec 11, 2025
- FDA report date
- Jan 21, 2026
- Quantity in commerce
- 7,720 units
- Distribution
- See key details
- FDA cause
- Under Investigation by firm
What is being recalled?
The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring of heparin therapy.
Affected model & UDI checker
Search the exact identifiers published for Z-1095-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| Not specified | The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring of heparin therapy. | Check source notice | 08426950078920 |
FDA code information
Part Number: 0020006800. UDI-DI: 08426950078920. Lot Number: N1136730. Expiration Date 12/31/2025.
Why was this product recalled?
Potential for microbial contamination.
These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.
What actions did Instrumentation Laboratory take?
Werfen notified consignees on about 12/11/2025 via URGENT MEDICAL DEVICE RECALL letter. Consignees were instructed to check inventory for affected lots and destroy any on hand, document any destruction on the provided Urgent Mandatory Tracking Form, inform all laboratory personnel of the notification, forward the notification to all affected departments and locations within each facility, retain a copy of the notification for records, and complete and return the Mandatory Response Tracking Form provided.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-1095-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 21, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 21, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology